Valeant Pharmaceuticals International (VRX) Receives News Sentiment Score of 0.01
News headlines about Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Valeant Pharmaceuticals International earned a news sentiment score of 0.01 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 45.263804364582 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news articles that may have effected Accern’s analysis:
- Valeant Pharmaceuticals International, Inc. (VRX) Rating Lowered to Sell at Vetr Inc. (americanbankingnews.com)
- ETFs with exposure to Valeant Pharmaceuticals International, Inc. : August 25, 2017 (finance.yahoo.com)
- Immune Design’s quest for a cancer vaccine could go the distance (finance.yahoo.com)
- Worth Watching Stock Valeant Pharmaceuticals International, Inc. (VRX) (vothemes.com)
- Valeant Pharmaceuticals International, Inc. (VRX) is at $14.39 per share and Arrowhead Pharmaceuticals, Inc. (ARWR … – Stocks Gallery (stocksgallery.com)
Several analysts have weighed in on VRX shares. BMO Capital Markets reiterated a “hold” rating and issued a $15.00 price objective on shares of Valeant Pharmaceuticals International in a research report on Thursday, July 27th. Zacks Investment Research upgraded Valeant Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research report on Thursday, July 27th. J P Morgan Chase & Co set a $10.00 price objective on Valeant Pharmaceuticals International and gave the company a “hold” rating in a research report on Monday, July 17th. Deutsche Bank AG set a $19.00 price objective on Valeant Pharmaceuticals International and gave the company a “hold” rating in a research report on Monday, July 17th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $35.00 price objective on shares of Valeant Pharmaceuticals International in a research report on Friday, June 30th. Five analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $17.72.
Shares of Valeant Pharmaceuticals International (NYSE VRX) opened at 14.14 on Monday. Valeant Pharmaceuticals International has a 52 week low of $8.31 and a 52 week high of $31.84. The company’s market capitalization is $4.93 billion. The company’s 50 day moving average price is $15.84 and its 200-day moving average price is $13.40.
Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last announced its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The company had revenue of $2.23 billion during the quarter, compared to analysts’ expectations of $2.23 billion. During the same period in the previous year, the company earned ($0.88) EPS. The business’s quarterly revenue was down 7.7% compared to the same quarter last year. Analysts anticipate that Valeant Pharmaceuticals International will post $3.89 earnings per share for the current fiscal year.
In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De purchased 10,000 shares of the firm’s stock in a transaction that occurred on Monday, August 21st. The stock was purchased at an average cost of $14.33 per share, with a total value of $143,300.00. Following the transaction, the director now owns 77,479 shares in the company, valued at $1,110,274.07. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.87% of the stock is owned by insiders.
About Valeant Pharmaceuticals International
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.